Poor Glycemic Control of Diabetes Mellitus Is Associated with Higher Risk of Prostate Cancer Detection in a Biopsy Population

Juhyun Park¹, Sung Yong Cho¹, Young Ju Lee², Seung Bae Lee¹, Hwancheol Son¹, Hyeon Jeong¹*

¹ Department of Urology, Seoul Metropolitan Government Seoul National University Boramae Medical Center, Dongjak-gu, Seoul, Korea, ² Department of Urology, Seoul National University Hospital 101, Daehak-Ro Jongno-gu, Seoul, Korea

Abstract

Objectives: To evaluate the impact of glycemic control of diabetes mellitus (DM) on prostate cancer detection in a biopsy population.

Patients and Methods: We retrospectively reviewed the records of 1,368 men who underwent prostate biopsy at our institution. We divided our biopsy population into three groups according to their history of DM, and their Hemoglobin A1c (HbA1c) level: a no-DM (DM−) group; a good glycemic control (DM+GC) group (HbA1c <6.5%); and a poor glycemic control (DM+PC) group (HbA1c ≥6.5%). For sub-analyses, the DM+PC group was divided into a moderately poor glycemic control (DM+PC group (6.5% ≤ HbA1c < 7.5%) and a severely poor glycemic control (DM+SPC) group (HbA1c ≥7.5%).

Results: Among 1,368 men, 338 (24.7%) had a history of DM, and 393 (28.7%) had a positive biopsy. There was a significant difference in prostatic specific antigen density (PSAD) (P = 0.037) and the frequency of abnormal DRE findings (P = 0.031) among three groups. The occurrence rate of overall prostate cancer (P<0.001) and high-grade prostate cancer (P = 0.016) also presented with a significantly difference. In the multivariate analysis, the DM+PC group was significantly associated with a higher rate of overall prostate cancer detection in biopsy subjects compared to the DM− group (OR = 2.313, P = 0.001) but the DM+PC group was not associated with a higher rate of high-grade (Gleason score ≥7) diseases detected during the biopsy (OR = 1.297, P = 0.376). However, in subgroup analysis, DM+SPC group was significantly related to a higher risk of high-grade diseases compared to the DM− group (OR = 2.446, P = 0.048).

Conclusions: Poor glycemic control of DM was associated with a higher risk of prostate cancer detection, including high-grade disease, in the biopsy population.

Introduction

The hypothesis that diabetes mellitus (DM) and prostate cancer have an inverse relationship was accepted as a medical fact quite recently. Especially, two meta-analysis papers published in 2004 and 2006 strongly supported this contention [1,2]. However, Chan JM and his colleagues announced that they could not find any evidence of the inverse relationship between DM and prostate cancer [3]. Some papers suggested that the relationship between DM and high-grade prostate cancer changed according to the activity of the patient, their body mass index (BMI), and ethnicity [4–6]. Several Asian papers also refuted the former hypothesis. Hong et al. concluded that DM was associated with a higher risk of detection of prostate cancer in a Korean population [7]. Two Japanese studies reported that DM was associated with aggressive or advanced prostate cancer [8,9].

Meanwhile, some studies researched the influence of DM by measuring hemoglobin A1c (HbA1c) level. To understand the effect of DM on prostate cancer, analyzing the difference according to the degree of glycemic control is considered as more appropriate rather than merely checking for the existence of a DM history. However, the studies about these subjects are lacking and the results have been controversial [10–14].

Consequently, we investigated the potential effect of DM according to the glycemic control level on prostate cancer detection in a biopsy population by using HbA1c measurements.
Materials and Methods

After institutional review board approval, we retrospectively reviewed the medical records of patients who underwent initial transrectal ultrasound-guided 12-core prostate biopsy at our clinic between January 2008 and October 2013. Indications for prostate biopsy were a serum prostate-specific antigen (PSA) level ≥4 ng/ml or a positive digital rectal examination (DRE) performed by urologists for all patients. Patients with a history of a previous biopsy at another institution, surgical treatment for prostatic disease, or incomplete clinical data were excluded from our study. An 18-gauge core biopsy needle and automatic spring-loaded biopsy gun were used. Systematic 12-core biopsies were performed at the apices, midportions, bases, and peripheral area of both planes. If patients had a target lesion (i.e., a hypoechoic lesion), and the site of the lesion was not included in the routine systematic 12-core biopsy sites, the uroradiologists conducted an additional biopsy of the target lesion.

Patient age, PSA level, DRE findings, DM history, HbA1c level, and prostate volume and the biopsy Gleason sum were analyzed to assess the potential association between the glycemic control of DM and prostate cancer detection. In addition, the effect on the detection of high-grade (Gleason ≥7) prostate cancer was analyzed.

The DM history was determined by primary physicians or internal medicine doctors. We checked HbA1c only if the patients had a history of DM, which we determined by taking their medical histories. We divided our biopsy population into three groups according to their history of DM, and HbA1c level: a no-DM (DM−) group; a good glycemic control (DM+GC) group (HbA1c <6.5%); and a poor glycemic control (DM+PC) group (HbA1c ≥ 6.5%). For subgroup analyses, the DM+PC group was divided into a moderately poor glycemic control (DM+mpc) group (6.5≤ HbA1c <7.5%) and a severely poor glycemic control (DM+spc) group (HbA1c ≥7.5%). Additionally, a subgroup analysis for age was assessed by decades, the PSA analysis was based on a cut-off level of 10 ng/ml. Obesity was defined as a BMI ≥25 kg/m².

We used Pearson’s Chi-square test, Fisher’s exact test, and the linear regression model to describe the relationship between the variables. Multivariate logistic and linear regression analysis was applied to examine the association between the glycemic control of DM and the prostate cancer on biopsy, adjusting for age, prostate volume, PSA level, and DRE findings. The association with the detection of high-grade cancer was similarly evaluated. Statistical significance was considered as P<0.05. All statistical analyses were performed using commercially available software (SPSS 14.0, Chicago, IL, USA).

Results

A total of 1,368 patients were included in the analysis, the mean age was 66.7 years and the median PSA level was 6.9 ng/ml. There were 338 men (24.7%) with a history of DM. Prostate cancer was detected from the biopsy in 393 (28.7%) patients and high-grade (Gleason score ≥7) prostate cancer was found in 263 (19.2%) (Table 1).

Table 2 shows the comparison among three groups by the degree of glycemic control based on the HbA1c level and the history of DM (DM−, DM+GC, DM+PC). There was a significant difference in prostate specific antigen density (PSAD) (P = 0.037) and the frequency of abnormal DRE findings (P = 0.031). The occurrence rate of overall prostate cancer was significantly different (P<0.001) and high-grade prostate cancer presented with a significantly different occurrence rate (P = 0.016).

In men with negative biopsies, the mean PSA level was 9.10 ng/ml in the DM− group, 7.32 ng/ml in the DM+GC group, and 7.28 ng/ml in the DM+PC group. These figures showed a significantly difference among the groups (P = 0.015).

The DM+PC group was significantly associated with a higher risk of detection of overall prostate cancer than the DM− group via biopsy in univariate (OR = 1.093, P = 0.002) and multivariate analyses (OR = 2.313, P = 0.001). Meanwhile, the DM+PC group was not associated with a higher rate of high-grade diseases compared to the DM− group in univariate (OR = 1.095, P = 0.721) and multivariate analyses (OR = 1.297 P = 0.376) (Table 3).

When we divided the DM+PC group for the subgroup analysis, there were 69 men in the DM+mpc group and 31 men in the DM+spc group. Multivariate analysis showed a significantly risk elevation of overall prostate cancer detection in both of the DM+mpc group (OR = 2.162, P = 0.011) and the DM+spc group (OR = 2.670, P = 0.022), compared to DM− group. In addition, the DM+PC group was significantly associated with a higher rate of high-grade prostate cancer detection than the DM− group in the multivariate analysis (OR = 2.444, P = 0.049).

When our analysis was limited to men with PSA <10 ng/ml, the DM+PC group was associated with a higher rate of overall prostate cancer detection compared to the DM− group from the biopsy in multivariate analysis (OR = 2.329 P = 0.003). However, multivariate analysis for high-grade prostate cancer showed no significant findings.

When stratified by age, only for men older than 60 years, the DM+PC group was significantly associated with a higher risk of overall prostate cancer detection than the DM− group in our biopsy population after multivariate analysis (OR = 2.111, P = 0.005), and it also applied for younger men (OR = 5.320, P = 0.016). In multivariate analysis for high-grade prostate cancer, there was no significant association for patients older than 60 years, whereas the DM+PC group showed borderline significance regarding the risk of high-grade prostate cancer detection for younger men (OR = 5.019, P = 0.056).

To check for the effect of obesity, we divided our biopsy population according to the presence of obesity (BMI ≥25 kg/m²) and undertook multivariate analysis. The DM+PC group was significantly associated with a higher rate of overall prostate cancer detection than the DM− group via biopsy, regardless of obesity status: non-obese men (OR = 2.715, P = 0.003) vs. obese men (OR = 2.344, P = 0.039). However, for the multivariate analysis of high-grade prostate cancer, there was no significant association.

Discussion

In 2004, Bonovas S. and colleagues presented a meta-analysis about DM and the risk of prostate cancer. They involved 14 studies, published between 1971 and 2002, and suggested that there was strong evidence that diabetic people had a significant decrease in risk for developing prostate cancer [1]. Subsequently, in 2006, Kasper JS and colleagues announced similar results through their meta-analysis study, which involved 19 studies between 1971 and 2005 [2]. They strengthened the former contention.

However, because a considerable number of pre-PSA-era patients were included in those meta-analyses, strong doubts had been raised concerning the reliability of the results from these meta-analyses. In fact, several studies which targeted post-PSA-era patients have reported different results, and contrary to previous studies, Chan JM et al. analyzed of 6,722 men diagnosed as prostate cancer from 1989 to 2002 within CaPSURE data, and
reported that any evidence of an inverse association between DM and prostate cancer risk was not observed [3]. On the other hand, Leitzmann MF et al. found out that a diabetic history was connected with a decreased risk of total prostate cancer among 33,088 men in the screening arm of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial in the late 2000s. However, through further analysis, they revealed that the association between diabetes and aggressive prostate cancer was suggestively positive for men who were lean (BMI, 25 kg/m²) [4].

Moreia DM et al. retrospectively investigated 998 multiethnic men who underwent prostate biopsy between 2001 and 2009, and reported that DM was associated with a greater risk of high-grade disease in obese white men [5].

Several Asian papers joined in these conflicting results about the relationship between DM and prostate cancer. Li Q et al. examined the Ohsaki cohort followed from 1995 to 2003, in which 230 new cases of prostate cancer were identified among 22,458 Japanese men. They identified that after stratification based on the clinical stage of prostate cancer, diabetic patients showed a higher risk of advanced prostate cancer with a multivariate analysis [8]. In addition, Fukushima et al. retrospectively evaluated 2,038 men who had undergone prostate biopsy and concluded that DM was

Table 1. Patient characteristics.

| Parameter                | No. Patient | Mean Age (range) | Median PSA (ng/ml, range) | Median PSAD (ng/ml², range) | No. abnormal DRE finding (%) | Mean prostate volume (ml, range) | No. DM (%) | No. high-grade Pca (GS ≥7) (%) | GS 7     | GS 3+4 | GS 4+3 | GS 8 | GS 9 | GS 10 |
|--------------------------|-------------|------------------|---------------------------|----------------------------|-------------------------------|---------------------------------|-------------|--------------------------------|----------|--------|--------|------|------|-------|
| No. Patient              | 1,368       | 66.7 (30–91)     | 6.9 (1.0–3081.0)          | 0.17 (0.03–13.32)          | 176 (12.9%)                   | 45.0 (9–262)                   | 338 (24.7%) | 393 (28.7%)                   | 263 (19.2%) | 131 (9.6%) | 76 (5.6%) | 55 (4.0%) | 73 (5.3%) | 18 (1.3%) | 12 (0.9%) |
| Mean age (range)         | 66.7 (30–91)| 66.0 (34–86)     | 6.1 (1.2–42.1)            | 0.14 (0.04–0.72)           | 27 (11.3%)                    | 45.5 (18–151)                  | 301 (29.2%) | 48 (20.2%)                    | 30 (12.6%) | 15 (6.3%) | 8 (3.4%) | 7 (7.0%) |
| Median PSA (ng/ml, range)| 7.2 (1.4–3081.0) | 6.0 (1.0–412.0) | 0.15 (0.03–1.37)          | 0.14 (0.04–0.72)           | 27 (11.3%)                    | 44.5 (14–126)                  | 211 (20.5%) | 30 (12.6%)                    | 15 (6.3%) | 10 (10.0%) | 8 (3.4%) | 7 (7.0%) |
| Median PSAD (ng/ml², range)| 0.18 (0.03–13.32) | 0.15 (0.03–1.37) | 0.14 (0.04–0.72)          | 0.037                      | 21 (10.0%)                    | 45.5 (18–151)                  | 106 (10.3%) | 15 (6.3%)                    | 10 (10.0%) | 8 (3.4%) | 7 (7.0%) | 3 (3.0%) |
| No. abnormal DRE finding (%)| 128 (12.4%) | 27 (11.3%)       | 21 (21.0%)                | 0.031                      | -                             | 7.4 (6.5–11.3)                 | 61 (5.9%) | 8 (3.4%)                    | 10 (10.0%) | 8 (3.4%) | 8 (8.0%) | 3 (3.0%) |
| Mean prostate volume (ml, range)| 45.0 (9–262) | 44.5 (14–126) | 45.5 (18–151)             | 0.949                      | -                             | 7.4 (6.5–11.3)                 | 45 (4.4%) | 7 (2.9%)                    | 3 (3.0%) | 8 (8.0%) | 8 (8.0%) | 3 (3.0%) |
| Mean HbA1c (range)       | 5.7 (4.4–6.4) | 7.4 (6.5–11.3)   | <0.001                    | <0.001                     | -                             | 7.4 (6.5–11.3)                 | 14 (1.4%) | 1 (0.4%)                    | 3 (3.0%) | 8 (8.0%) | 8 (8.0%) | 3 (3.0%) |
| No. overall Pca (%)      | 301 (29.2%) | 48 (20.2%)       | 44 (44.0%)                | <0.001                     | -                             | 7.4 (6.5–11.3)                 | 11 (1.1%) | 1 (0.4%)                    | 3 (3.0%) | 8 (8.0%) | 8 (8.0%) | 3 (3.0%) |

Table 2. Patient characteristics and biopsy outcomes according to glycemic control of DM.

| Variables                | DM—       | DM+GC  | DM+PC  | P-value |
|--------------------------|-----------|--------|--------|---------|
| No. Patient              | 1,030     | 238    | 100    |         |
| Mean Age (range)         | 66.7 (30–91)| 66.0 (34–86)| 67.8 (47–83)| 0.210   |
| Median PSA (ng/ml, range)| 7.2 (1.4–3081.0) | 6.0 (1.0–412.0) | 6.1 (1.2–42.1) | 0.207   |
| Median PSAD (ng/ml², range)| 0.18 (0.03–13.32) | 0.15 (0.03–1.37) | 0.14 (0.04–0.72) | 0.037   |
| No. abnormal DRE finding (%)| 128 (12.4%) | 27 (11.3%) | 21 (21.0%) | 0.031   |
| Mean prostate volume (ml, range)| 45.0 (9–262) | 44.5 (14–126) | 45.5 (18–151) | 0.949   |
| Mean HbA1c (range)       | 5.7 (4.4–6.4) | 7.4 (6.5–11.3) | <0.001   | <0.001  |
| No. overall Pca (%)      | 301 (29.2%) | 48 (20.2%) | 44 (44.0%) | <0.001  |
| No. high-grade Pca (GS ≥7) (%)| 211 (20.5%) | 30 (12.6%) | 22 (22.0%) | 0.016   |
| GS 7                     | 106 (10.3%)| 15 (6.3%) | 10 (10.0%) |         |
| GS 3+4                   | 61 (5.9%)  | 8 (3.4%) | 7 (7.0%)  |         |
| GS 4+3                   | 45 (4.4%)  | 7 (2.9%) | 3 (3.0%)  |         |
| GS 8                     | 57 (5.5%)  | 8 (3.4%) | 8 (8.0%)  |         |
| GS 9                     | 14 (1.4%)  | 1 (0.4%) | 3 (3.0%)  |         |
| GS 10                    | 11 (1.1%)  | 1 (0.4%) | 0 (0%)    |         |

DM, diabetes mellitus; DM—, no DM; DM+GC, DM with good glycemic control, HbA1c <6.5%; DM+PC, DM with poor glycemic control, HbA1c ≥6.5%; PSA, prostate-specific antigen; PSAD, prostate-specific antigen density; DRE, digital rectal examination; Pca, prostate cancer; GS, Gleason Score. doi:10.1371/journal.pone.0104789.t001
associated with more aggressive prostate cancer detection among obese Japanese patients with PSA level <10 ng/ml [9]. Hong et al. reviewed 3,925 men undergoing prostate biopsy and described that DM was significantly associated with a higher risk of overall prostate cancer detection and high-grade prostate cancer in a Korean biopsy population [7].

Meanwhile, some papers tried to investigate the role of glycemic control, as measured by HbA1c, on prostate cancer beyond the simple comparison of diabetic men versus non-diabetic men. Kim HS et al. identified 247 men from the Shared Equal Access Regional Cancer Hospital (SEARCH) database and detected men with higher HbA1c levels presented with more biologically aggressive prostate cancers at radical prostatectomy [10]. Hong et al. reported similar results. They reviewed 740 patients who underwent radical prostatectomy for clinically localized prostate cancer and announced that glycemic control, as represented by the HbA1c level, may be a useful preoperative predictor of aggressive tumor profiles among diabetic patients [11]. On the contrary, Omitolo AA et al. examined 9,486 type 2 DM patients and reported that prostate cancer risk would be increased paradoxically in DM with poor glycemic control, HbA1c ≥ 6.5%; DM+GC, DM with good glycemic control, HbA1c < 6.5%; DM+PC, DM with poor glycemic control, HbA1c ≥ 6.5%. Some papers have suggested that DM could have an influence on prostate cancer due to hormonal imbalance. The authors of those papers said that in diabetic patients there is a cause and effect relationship between hyperinsulinemia, low testosterone levels, and low PSA levels [16–19]. Supplementally, we expected that the effect of DM on prostate cancer would be different depending upon the degree of glycemic control. In this study, when we analyzed the patients with negative biopsy, the PSA level was significantly different on prostate cancer wound be different depending upon the degree of glycemic control. In our study, there were no significant results by the simple comparison of diabetic men versus non-diabetic men. Kim et al. reviewed 3,925 men undergoing prostate biopsy and described that DM was significantly associated with a higher risk of overall prostate cancer detection and high-grade prostate cancer in a Korean biopsy population [7].

Meanwhile, some papers tried to investigate the role of glycemic control, as measured by HbA1c, on prostate cancer beyond the simple comparison of diabetic men versus non-diabetic men. Kim HS et al. identified 247 men from the Shared Equal Access Regional Cancer Hospital (SEARCH) database and detected men with higher HbA1c levels presented with more biologically aggressive prostate cancers at radical prostatectomy [10]. Hong et al. reported similar results. They reviewed 740 patients who underwent radical prostatectomy for clinically localized prostate cancer and announced that glycemic control, as represented by the HbA1c level, may be a useful preoperative predictor of aggressive tumor profiles among diabetic patients [11]. On the contrary, Omitolo AA et al. examined 9,486 type 2 DM patients and reported that prostate cancer risk would be increased paradoxically in DM with poor glycemic control, HbA1c ≥ 6.5%; DM+GC, DM with good glycemic control, HbA1c < 6.5%; DM+PC, DM with poor glycemic control, HbA1c ≥ 6.5%.

Table 3. Odds ratio of DM groups being associated with overall prostate cancer or high-grade (Gleason score ≥ 7) prostate cancer detection on prostate biopsy.

| Overall prostate cancer detection (Unadjusted) | Adjusted | Unadjusted | Adjusted |
|---------------------------------------------|----------|------------|----------|
| OR (95% CI) | P-value | OR (95% CI) | P-value |
| Age | 1.059 (1.043–1.076) | <0.001 | 1.062 (1.043–1.081) | <0.001 |
| PSA | 1.043 (1.030–1.056) | <0.001 | 1.051 (1.033–1.069) | <0.001 |
| Prostate volume | 0.974 (0.966–0.981) | <0.001 | 0.957 (0.948–0.966) | <0.001 |
| Abnormal DRE finding | 2.341 (1.661–3.300) | <0.001 | 1.556 (1.033–2.345) | 0.034 |
| DM− | reference | - | reference | - |
| DM+GC | 0.612 (0.434–0.863) | 0.005 | 0.759 (0.517–1.115) | 0.160 |
| DM+PC | 1.903 (1.254–2.888) | 0.002 | 2.313 (1.408–3.799) | 0.001 |

| High-grade prostate cancer (Unadjusted) | Adjusted | Unadjusted | Adjusted |
|----------------------------------------|----------|------------|----------|
| OR (95% CI) | P-value | OR (95% CI) | P-value |
| Age | 1.062 (1.043–1.082) | <0.001 | 1.057 (1.035–1.079) | <0.001 |
| PSA | 1.039 (1.027–1.051) | <0.001 | 1.066 (1.046–1.085) | <0.001 |
| Prostate volume | 0.973 (0.965–0.982) | <0.001 | 0.951 (0.940–0.963) | <0.001 |
| Abnormal DRE finding | 1.967 (1.351–2.865) | <0.001 | 1.270 (0.803–2.008) | 0.307 |
| DM− | reference | - | reference | - |
| DM+GC | 0.560 (0.371–0.845) | 0.006 | 0.692 (0.434–1.104) | 0.122 |
| DM+PC | 1.095 (0.666–1.799) | 0.721 | 1.297 (0.729–2.307) | 0.376 |

OR, odds ratio for positive biopsy; CI, confidence interval; DRE, digital rectal examination; DM, diabetes mellitus; DM−, no DM; DM+GC, DM with good glycemic control, HbA1c < 6.5%; DM+PC, DM with poor glycemic control, HbA1c ≥ 6.5%.

doi:10.1371/journal.pone.0104789.t003
36 patients that showed excessive PSA, but with 50 or more of the total patients, PSA and PSAD were significantly lower than in the non-diabetic group, while prostate volume was no different. Several studies about the relationship between DM and prostate cancer have reported lower PSA in diabetic groups. These studies have presented the following reasons for such findings: 1) the impact of growth factors and hormone-related DM, 2) the effects of anti-diabetic drugs, and 3) intraprostatic vascular damage due to DM [25,26]. Further research should clarify whether the changes in PSA or PSAD among different groups are found in general populations as well as biopsy populations.

Additionally, we could have found that abnormal DRE findings were more common in DM+PC group. However, there was no significant difference in the abnormal DRE findings when we re-division the biopsy population into a DM group and a non-DM group (p = 0.097). Studies showing that the frequency of abnormal DRE findings were different depending on the degree of DM control are rare. In fact, ours may be the first such report. These findings should be verified through other studies in the future. Meanwhile, in our study, abnormal DRE findings were associated with overall prostate cancer detection, but were not a significant factor in high-grade prostate cancer detection.

In this study, from among the 1,368 patients suffering from biopsy complications, 16 men required hospitalization and additional antibiotic medication. The incidence of complications did not vary according to the presence or absence of DM. Carignan et al. have reported that in an analysis of 5,789 cases of prostate biopsies, DM was found to be one of the factors that can increase the risk of urinary sepsis as a biopsy complication [27].

Our study may be limited by its retrospective nature. Recently, there have been several reports about the effect of anti-diabetic drugs on prostate cancer. In particular, the relationship between metformin and prostate cancer is currently a hot issue [28–30].

References
1. Bonovas S, Filoussi K, Tsantes A (2004) Diabetes mellitus and risk of prostate cancer: a meta-analysis. Diabetesologia 47: 1071–1078.
2. Kaspar JS, Giovannucci E (2006) A meta-analysis of diabetes mellitus and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 15: 2056–2062.
3. Chan JM, Latini DM, Cowan J, Duchaine J, Carroll PR (2005) History of diabetes, clinical features of prostate cancer, and prostate cancer recurrence—data from CaPSURE (United States). Cancer Causes Control 16: 789–797.
4. Leitzmann MF, Alf J, Albanes D, Huang AW, Schatzkin A, et al. (2008) Diabetes mellitus and prostate cancer risk in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Cancer Causes Control 19: 1267–1276.
5. Moreira DM, Anderson T, Gerber L, Thomas J-A, Batenb LL, et al. (2011) The association of diabetes mellitus and high-grade prostate cancer in a multiethnic biopsy series. Cancer Causes Control 22: 927–933.
6. Fall K, Garmo H, Gudbjornsdotir S, Stattin P, Zedelius B (2013) Diabetes mellitus and prostate cancer risk; a nationwide case-control study within PCBSa Sweden. Cancer Epidemiol Biomarkers Prev 22: 1102–1109.
7. Hong SK, Oh JJ, Byun SS, Hwang SI, Lee HJ, et al. (2012) Impact of diabetes mellitus on the detection of prostate cancer via contemporary multi-core prostate biopsy. Prostate 72: 51–57.
8. Li Q, Kuriyama S, Kakizaki M, Yan H, Sone T, et al. (2010) History of diabetes mellitus and the risk of prostate cancer: the Ohsaki Cohort Study. Cancer Causes Control 21: 1025–1032.
9. Fukushima H, Matsub H, Kawakami S, Ito M, Sakura M, et al. (2012) Effect of diabetes mellitus on high-grade prostate cancer detection among Japanese obese patients with prostate-specific antigen less than 10 ng/mL. Urology 79: 1329–1334.
10. Kim HS, Presni JC, Arnon WN, Terris MK, Kane CJ, et al. (2010) Glycemic control and prostate cancer progression: results from the SEARCH database. Prostate 70: 1540–1546.
11. Hong SK, Lee ST, Kim SS, Min KE, Byun SS, et al. (2009) Significance of preoperative HbA1c level in patients with diabetes mellitus and clinically localized prostate cancer. Prostate 69: 820–826.
12. Oitiu AA, Stankowski RV, Berg RL, Engel JM, Glueck I, et al. (2013) Type 2 diabetes mellitus, glycemic control, and cancer risk. Eur J Cancer Prev.
13. Ozhek E, Onanucrem A, Dursun M, Sahin S, Besirouglu H, et al. (2014) Diabetes mellitus and HbA1c levels associated with high grade prostate cancer. Asian Pacific journal of cancer prevention: APJCP 15: 2553–2558.
14. de Beer JC, Liebersch I (2014) Does cancer risk increase with HbA1c, independent of diabetes? British journal of cancer 110: 2361–2368.
15. (2010) Standards of medical care in diabetes—2010. Diabetes care 33 Suppl 1: S11–61.
16. Arcidiacono B, Iritano S, Nocera A, Possidente K, Nevolo MT, et al. (2012) Insulin resistance and cancer risk: an overview of the pathogenic mechanisms. Experimental diabetes research 2012: 789174.
17. Brand JS, Waterham NJ, Dosssett M, Folkers E, van der Schouw YT, et al. (2011) Associations of endogenous testosterone and SHBG with glycated haemoglobin in middle-aged and older men. Clinical endocrinology 74: 572–576.
18. Grossmann M, Gianatti FJ, Zajac JD (2010) Testosterone and type 2 diabetes. Current opinion in endocrinology, diabetes, and obesity 17: 247–256.
19. Redlmann AW, Allen NE, Appleyard P, Key TJ, Ferrucci L, et al. (2008) Insulin-like growth factors, their binding proteins, and prostate cancer risk: analysis of individual patient data from 12 prospective studies. Ann Intern Med 149: 461–471, W463–468.
20. Kim HJ, Kim BH, Park CH, Kim CJ (2012) Usefulness of preoperative serum testosterone as a predictor of extraprostatic extension and biochemical recurrence. Korean journal of urology 53: 9–13.
21. Salonia A, Abdollah F, Capitanio U, Suardi N, Briganti A, et al. (2012) Serum sex steroids depict a nonlinear u-shaped association with high-risk prostate cancer at radical prostatectomy. Clinical cancer research: an official journal of the American Association for Cancer Research 18: 3648–3657.
22. Teloken C, Da Ros CT, Caraver F, Weber FA, Carvalheiro AP, et al. (2005) Low serum testosterone levels are associated with positive surgical margins in radical

Conclusions
Poor glycemic control of DM was associated with a higher risk of prostate cancer detection, including high-grade (Gleason score ≥7) disease, in the biopsy population. Further studies should be undertaken to elucidate the exact biological mechanism that exists between DM and prostate cancer.

Ethical Standards
This study design and the use of patients’ information stored in the hospital database were approved by the Institutional Review Board (IRB) at the Seoul Metropolitan Government - Seoul National University Borame Medical Center. The approval number is 26-2013-84. We were given exemption from getting informed consents by the IRB because the present study is a retrospective study and personal identifiers were completely removed and the data were analyzed anonymously. Our study was conducted according to the ethical principles laid down in the 1964 Declaration of Helsinki and its later amendments.

Acknowledgments
This study was supported by Grant No. 03-2014-5 from the Seoul National University Hospital (SNUH) Research Fund.

Author Contributions
Conceived and designed the experiments: JHP SYC HJ. Performed the experiments: JHP SYC YJL SBL HCS HJ. Analyzed the data: JHP SYC. Contributed reagents/materials/analysis tools: SYC. Contributed to the writing of the manuscript: JHP SYC HJ.
retropubic prostatectomy: hypogonadism represents bad prognosis in prostate cancer. The Journal of urology 174: 2178–2180.

23. Yamamoto S, Yonese J, Kawakami S, Ohkubo Y, Tatokoro M, et al. (2007) Preoperative serum testosterone level as an independent predictor of treatment failure following radical prostatectomy. European urology 52: 696–701.

24. Xylinas E, Ploussard G, Durand X, Fabre A, Salomon L, et al. (2011) Low pretreatment total testosterone (<3 ng/mL) predicts extraprostatic disease in prostatectomy specimens from patients with preoperative localized prostate cancer. BJU international 107: 1400–1403.

25. Naito M, Asai Y, Mori A, Fukada Y, Kawabara M, et al. (2012) Association of obesity and diabetes with serum prostate-specific antigen levels in Japanese males. Nagoya journal of medical science 74: 285–292.

26. Pierce BL, (2012) Why are diabetics at reduced risk for prostate cancer? A review of the epidemiologic evidence. Urologic oncology 30: 735–743.

27. Carignan A, Roussy JF, Lapointe V, Valiquette L, Sabagh R, et al. (2012) Increasing risk of infectious complications after transrectal ultrasound-guided prostate biopsies: time to reassess antimicrobial prophylaxis? European urology 62: 453–459.

28. Akinyeke T, Matsumura S, Wang X, Wu Y, Schaller ED, et al. (2013) Metformin targets c-MYC oncogene to prevent prostate cancer. Carcinogenesis 34: 2823–2832.

29. Margel D, Urbach DR, Lipscombe LL, Bell CM, Kuikarni G, et al. (2013) Metformin use and all-cause and prostate cancer-specific mortality among men with diabetes. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 31: 3069–3075.

30. Tsilidis KK, Capothanassi D, Allen NE, Rizos EC, Lopez DS, et al. (2014) Metformin Does Not Affect Cancer Risk: A Cohort Study in the U.K. Clinical Practice Research Datalink Analyzed Like an Intention-to-Treat Trial. Diabetes care.